tbuckley/cabot-search huggingface dataset:
Políticas nacionales en materia de prevención de resistencias a los agentes antimicrobianos: situación de 17 países europeos a finales de 2000
Authors: H Therre
Journal: Eurosurveillance (2001)

Un estudio realizado en los Estados Miembros de la Union Europea y en Noruega demuestra que, en diciembre de 2000, todos los paises, salvo dos, contaban con un sistema nacional de vigilancia de microorganismos resistentes a antibioticos. En Italia, Irlanda y Escocia, los sistemas se han implantado muy recientemente (respectivamente en 1998, 1999 y 1999). Asimismo, todos los paises, salvo Irlanda y Escocia, cuentan con un sistema nacional de recogida de datos sobre el consumo de antibioticos; concretamente, desde el 2000, en Austria, Italia y Luxemburgo. Algunos de estos sistemas fueron creados despues de 1998 a raiz de la publicacion de las recomendaciones de la conferencia europea ‘La amenaza microbiana’ celebrada en Copenhague. Por otra parte, desde entonces se han adoptado otras medidas: campanas de educacion dirigidas a la poblacion de Inglaterra y Gales, Irlanda o Francia, creacion de comites encargados especificamente de la vigilancia del consumo de antibioticos en Italia, o de la prevencion de resistencias en Belgica o en Irlanda, publicacion de recomendaciones sobre el uso adecuado de antibioticos en Austria y en Finlandia, etc.
David Gwyn Seymour
Authors: Ruth Seymour
Journal: BMJ (2017)

David Gwyn Seymour (“Gwyn”) was born in Ynysybwl near Pontypridd in south Wales and qualified from Birmingham University in 1973. After rapid acquisition of his MRCP (UK) in 1975, he entered the registrar level of rotational training at the Canadian University of Western Ontario (1975-77). He then obtained a senior registrar post in the department of geriatric medicine in Dundee (1977-82) followed by a senior lectureship in medicine for the elderly in Cardiff (1982-1994). He took up the chair of medicine for the elderly in Aberdeen in 1994 and retired in 2009. Although his CV is straightforward, the man who made this journey was, in his quiet, self effacing way, a trail-blazer. This obituary pays homage to just three of the stops along the way and finishes with a recognition of one of his lasting legacies to all of us.

Ynysybwl is a mining village in the south Wales coalfield, and Gwyn, the only child of loving, supportive parents—Mair and Haydn Seymour—came from three generations of men in the mining industry. He was immensely proud of …
HOUT-19. DEVELOPMENT OF A NOVEL BURDEN SURVEY FOR CAREGIVERS OF GLIOBLASTOMA MULTIFORME (GBM) PATIENTS
Authors: Trang Au, Hillevi Bauer, Junjie Ma, Ryan Nelson, Alexandre Watanabe, Prianka Singh, Beata Korytowsky, Elizabeth Wilson, Nicole Willmarth, Adam Cohen, Howard Colman, David Stenehjem, Diana Brixner
Journal: Neuro-Oncology (2017)

Glioblastoma multiforme (GBM) is an incurable brain cancer associated with a grim prognosis. Afflicted individuals often experience rapid decline in cognitive function, with implications on quality of life and support systems. Although the complexity of GBM to patients has been reported, less is known about its impact on caregivers. We developed a survey tool to evaluate caregiver experience with an emphasis on caregiver burden. A literature review of caregiver studies in other cancers, Alzheimer’s disease, and dementia was conducted. A preliminary survey was drafted followed by consultation with neuro-oncologists and patient advocates to further define relevant domains and questions. Next, we conducted individual caregiver interviews with a random convenience sample of 10 self-identifying primary caregivers of adult patients receiving care for GBM at Huntsman Cancer Institute, Salt Lake City, Utah. Caregivers were asked to review the survey from their perspective; specifically to rank domains, identify aspects of caregiving currently absent from the survey, and provide input on questions to be eliminated. Five domains related to caregiver burden were identified: 1) emotional health of caregiver; 2) change in cognitive function of loved one with GBM; 3) information needs; 4) caregiver tasks; and 5) medical/non-medical caregiver burden. Although caregivers reported all domains were important, “Emotional health of caregiver” was voted as the most important domain and “Information needs” was ranked last. The survey will be refined with findings from caregiver interviews, including new areas of interest, i.e. relationship impact, travel logistics, and reality of living “scan to scan”. Further, consultation with a psychometrician will ensure the survey is an appropriate tool to measure caregiver burden, after which a pilot of the survey will be conducted before final dissemination. Direct caregiver feedback provides valuable insight towards development and validation of a survey tool to measure caregiver burden in GBM.
Arthritis in Melorheostosis-An Uncommon Feature in a Rare Disease
Authors: Enrico Selvi, Marco Bardelli, Giacomo Maria Guidelli
Journal: Arthritis & Rheumatology (2017)

A 53-year-old male developed left knee and left ankle arthritis associated with marked induration of the skin and soft tissues distal to the knees. The left knee was swollen, tender, and with a non-reducible contracture and similarly the left ankle and the subtalar joint were stiff and moderately swollen. In addition, diffuse, bluish, small vascular ectasia, hypertrichosis and skin pigmentation of the affected sites were evident (fig1). These symptoms began 20 years before and the patient had been diagnosed with eosinophilic fasciitis and treated with daily prednisone leading to partial improvement of the symptoms, but not of the knee deformity and soft tissue induration.

This article is protected by copyright. All rights reserved.
Skin rash and response to cetuximab treatment: a retrospective single-center analysis
Authors: M.C. Cau, R. Puxeddu, G. Tore, S. Pirri, Z. Pusceddu, C. Aste, F. Carta, O. Summo, I. Tandurella, P. Carta, M.G. Aste, E. Defraia, G. Gutman, L. Mascia, M.G. Mascia, M. Ghiani
Journal: Annals of Oncology (2017)
P3.13-009 Rapid Detection of Lung Cancer by Fluorescent Imaging Using A γ-Glutamyltranspeptidase-Activatable Fluorescent Probe
Authors: M. Mun, Y. Sakao, J. Ichinose, Y. Matsuura, M. Nakao, K. Nakagawa, H. Ninomiya, N. Motoi, Y. Urano, S. Okumura, Y. Ishikawa
Journal: Journal of Thoracic Oncology (2017)
Comorbidity scores as predictive tools for nivolumab toxicity in patients with advanced non small cell lung cancer (NSCLC): preliminary results of a prospective multicenter study
Authors: E. Quaquarini, F. Sottotetti, R. Palumbo, A. Gambaro, A. Ferzi, M. Frascaroli, C. Teragni, B. Tagliaferri, E. Pozzi, L. Licata, G. Massa, A. Bernardo
Journal: Annals of Oncology (2017)
P3.04-003 Phase II Trial of Atezolizumab Before and After Definitive Chemoradiation for Patients with Unresectable Stage III NSCLC
Authors: H. Ross, D. Kozono, J. Urbanic, T. Williams, C. Dufrane, I. Bara, M. Gandhi, K. Schulze, J.M. Brockman, X. Wang, E. Vokes, T. Stinchcombe
Journal: Journal of Thoracic Oncology (2017)
Tendencias del SIDA en Europa: disminución en occidente, aumento en el este
Authors: F F Hamers, A M Downs, J Alix, J B Brunet
Journal: Eurosurveillance (1997)

En 1.996, se declararon 24.920 casos de SIDA en la Region Europea de la OMS, lo que llevo a un total acumulado de 185.808 casos, incluidos 6.969 (4%) casos pediatricos (<13 anos) (1). Por primera vez desde el inicio de la epidemia, ha disminuido la cifra anual de casos declarados (un 5% entre 1.995 y 1.996, despues de un aumento del 1% en 1.995).
P1.07-036 LC-HRMS Metabolomics Profiling in Advanced NSCLC Treated with Anti PD-1 Agents. Metabolic Features at Diagnosis and at Response Evaluation
Authors: A.L. Ortega Granados, F.J. García Verdejo, N. Cárdenas Quesada, M. Ruiz Sanjuan, C. Díaz Navarro, C. De La Torre Cabrera, M. Fernández Navarro, G. Pérez Chica, F. Vicente Pérez, M.Á. Moreno Jiménez, N. Luque Caro, B. Márquez Lobo, A. Jaén Morago, R. Dueñas García, E. Martínez Ortega, P. Sánchez Rovira, J. Pérez Del Palacio
Journal: Journal of Thoracic Oncology (2017)
MA 04.01 Prospective Comparative Evaluation of Patient and Caregiver Perspectives on a Multidisciplinary Model of Lung Cancer Care
Authors: K. Ward, M. Smeltzer, F. Rugless, N. Faris, M. Ray, B. Jackson, C. Foust, A. Patel, M. Meadows, N. Boateng, K. Roark, F. Crossley, G. Oliver, L. Mchugh, W. Hastings, O. Osborne, J. Osborne, T. Ill, M. Ill, R. Signore, R. Fox, E. Robbins, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2017)
EPID-12. INCIDENCE AND SURVIVAL TRENDS FOR MEDULLOBLASTOMAS IN THE UNITED STATES FROM 2001 TO 2013
Authors: Vishesh Khanna, Rebecca Achey, Quinn Ostrom, Hunter Block-Beach, Carol Kruchko, Jill Barnholtz-Sloan, Peter de Blank
Journal: Neuro-Oncology (2017)

Population-based data examining recent epidemiological trends in medulloblastoma, the most common pediatric brain malignancy, are limited. Therefore, we sought to examine recent population-level trends in medulloblastoma incidence and survival. Central Brain Tumor Registry of the United States (CBTRUS) data were analyzed from 2001–2013. Age-adjusted incidence rates (IR), annual percent changes (APCs) with 95% confidence intervals (CI) were calculated by age, sex, and race. Relative survival rates were calculated by age, sex, and race using Surveillance, Epidemiology and End-Results (SEER) registries; a subset of CBTRUS data. Kaplan-Meier and Cox proportional hazards models were used to examine survival differences. Medulloblastoma incidence remained relatively stable from 2001–2013, with minor fluctuations from 2001–2009 (APC=2.2, 95%CI: 0.8, 3.5) and 2009–2013 (APC=-4.1, 95%CI: -7.5, -0.6). Incidence was highest in patients aged 1–4 years at diagnosis, but patients aged 10–14 years showed increased incidence from 2000–2013 (APC=3.2, 95%CI: 0.6, 5.8). Males displayed higher IR relative to females (males: 0.16 vs. females: 0.12), except in patients <1 year-old. Compared to Whites, Blacks displayed a non-significant increase in incidence (APC=1.7, 95%CI: -0.4, 4.0) and in mortality risk (hazard ratio for survival =0.74; p=0.09). The current study reports no overall change in medulloblastoma incidence from 2001–2013. Male and female patients <1 year-old had equal medulloblastoma incidence rates and poor 5-year relative survival compared to other ages. Non-significant trends in the data suggest disparities in medulloblastoma incidence and survival by race. Thus, analysis of tumor-specific trends by demographic variables can uncover clinically informative trends in cancer burden.
HOUT-15. BRAIN TUMOR PATIENT AND CAREGIVER SURVEY ON CLINICAL TRIALS: IDENTIFYING ATTITUDES AND BARRIERS TO PATIENT PARTICIPATION
Authors: Amanda J Bates, Samantha A Couillard, David F Arons, W K Alfred Yung, Michael Vogelbaum, Patrick Y Wen, Ann E Kingston
Journal: Neuro-Oncology (2017)

The National Brain Tumor Society conducted an online survey to determine if, when, and how information about clinical trials is provided to brain tumor patients and their caregivers, as well as to understand the perceptions and barriers around clinical trial participation. Questions were tailored for either patient or caregiver respondents, each with further stratification based on whether the patient was newly diagnosed/first occurrence or diagnosed with a recurrent primary brain tumor. There was a total of 1,463 respondents, of which 54% were caregivers with 73% of patients having/had first occurrence brain tumors. Among the different brain tumor types represented in the sample, glioblastoma made up the majority (36%), followed by meningioma (18%), astrocytoma (17%), oligodendroglioma (11%) and a mix of other types (29%), with 2% of respondents unsure of their diagnosis. The survey was open to brain tumor metastases patients, but an insufficient number of respondents met the true definition of "metastatic" preventing their inclusion in the overall analysis. When asked if patients had been informed about clinical trials by their medical team, 42% reported being informed, while 36% stated they had never discussed clinical trials with their provider. When patients were informed about clinical trials, only 24% were informed at the time of their diagnosis. Of the total sample, 21% of patients had participated in a clinical trial. When asked why patients had not participated in clinical trials, the top reasons given were: 1) the patient's provider did not recommend participating in the trial, 2) the patient did not qualify for clinical trial(s), and 3) the patient and caregiver did not know where to find a clinical trial. The survey results underscore the need for better resources and decision support that will enable patients to be more fully informed about the importance of their participation in appropriately matched clinical trials.
IMMU-67. UNLOCKING THE PROMISE OF MYXOMA VIRUS THERAPY: COMBINATION OF RADIATION PLUS CRIZOTINIB OR BEVACIZUMAB TO ENHANCE EFFICACY IN GLIOBLASTOMA
Authors: Arabinda Das, Eric Bartee, Jennifer Oletsky, Daniel G McDonald, William Alexander Vandergrift, Abhay K Varma, Kenneth N Vanek, Pierre Giglio, Sunil J Patel, Scott M Lindhorst, David Cachia
Journal: Neuro-Oncology (2017)

Glioblastoma (GB) is the most common and highly aggressive adult brain cancer. Dysfunction of receptor tyrosine kinases, such as ALK, c-Met and VEGF have all been implicated in the progression of this malignancy and resistance to therapy. Traditional therapeutic strategies targeting ALK/c-Met or VEGF have not yet given satisfactory outcomes. Myxoma virus (MYXV) is a novel oncolytic virus that has been shown to replicate in GB models. Here, we investigated the efficacy of MYXV as monotherapy, or in combination with 1 Gy radiation plus c-Met/ALK inhibitor crizotinib and VEGF inhibitor bevacizumab in different cell lines (GL261, T9, and U118) surgically obtained from GB patients. We investigated the molecular mechanisms of apoptotic death by Western blots. Colorimetric assay demonstrated that treatment with MYXV plus radiation with crizotinib or bevacizumab caused apoptosis due to an increase in activation of caspase-3 and decrease in expression of Bcl-2 proteins in GB cells and tissues. Most importantly, MYXV plus radiation significantly enhanced the anti-cancer effect of crizotinib, bevacizumab and temozolomide, in GB cell lines as well as in fresh tumor biopsies from GB patients. Our studies also suggest that induction of apoptosis by MYXV does not depend on the functional status of the GB cell lines or in the GB tissues. Further studies in different animal models of GB are warranted in the future to determine whether MYXV in combination with radiation, crizotinib or bevacizumab may be useful as anti-cancer agent for the management of human GBs in vivo.
P1.15-005 Relationship Between MYC Family Status and Sensitivity to Aurora Kinase Inhibitors in Neuroendocrine and Other Lung Cancer Cell Lines
Authors: T. Haruki, M. Papari-Zareei, W. Zhang, Y. Zhang, V. Stastny, J. Minna, A. Gazdar
Journal: Journal of Thoracic Oncology (2017)
P2.03b-012 A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer
Authors: Seema Nagpal, Heather Wakelee, Sukhmani Padda, Sophie Bertrand, Brenda Acevedo, Alison Holmes Tisch, Judy Pagtama, Scott Soltys, Joel Neal
Journal: Journal of Thoracic Oncology (2017)
Vigilancia de la tuberculosis en la Región Europea de la OMS, 1995-1996
Authors: D Antoine, V Schwoebel, J Veen, M. C. Raviglione, H. L. Rieder
Journal: Eurosurveillance (1998)

Creado en 1996, el programa EuroTB para la vigilancia de la tuberculosis (TB) en Europa tiene como objetivo recoger, analizar y difundir datos sobre casos de tuberculosis declarados en la Region Europea de la Organizacion Mundial de la Salud (OMS). Como continuacion al estudio de viabilidad realizado en 1996-1997 sobre los casos declarados en 1995 (1), se ha instituido un metodo sistematico de recogida de datos. El programa se gestiona conjuntamente por el Centro Europeo para la Vigilancia Epidemiologica del SIDA (CESES) en Saint-Maurice, Francia y la Asociacion para la Tuberculosis (KNCV) de La Haya, Paises Bajos.
P1.04-004 Phase I/Ib Study of Nivolumab and Veliparib in Advanced Solid Tumors and Lymphoma with and without Alterations in Selected DNA Repair Genes
Authors: Y. Chae, W. Iams, S. Pai, R. Costa, T. Taxter, N. Mohindra, V. Villaflor, B. Pro, F. Giles
Journal: Journal of Thoracic Oncology (2017)
STEM-05. THE CONSERVED TUMOR SUPPRESSOR LGL1 REGULATES ADULT OLIGODENDROCYTE PROGENITOR CELL DIVISION MODE AND PREVENTS PREMALIGNANT PHENOTYPES
Authors: Mathieu Daynac, Claudia Petritsch
Journal: Neuro-Oncology (2017)

Mammalian oligodendrocyte progenitor cells (OPC) divide asymmetrically by dispatching pro-mitotic NG2, EGFR and PDGFRalpha, from here on called the NG2 complex, unequally between daughter cells to establish a cell fate bias and to restrict proliferation. Studies in genetically engineered mouse models have shown that OPC are a putative cellular origin of glioma and have furthermore suggested that asymmetric divisions are tumor suppressive and can be exploited therapeutically. The objective of this project is to test directly if disruption of asymmetric divisions causes premalignant phenotypes and even neoplastic transformation. To reach this objective, we study the hypothesisthat a mammalian gene called Lethal giant Larvae, Lgl1 regulates asymmetric OPC divisions. Lgl1 is frequently inactivated and its expression is lost in glioma. We propose that genetically enforced deletion of Lgl1 will disrupt asymmetric divisions and lead to premalignant changes and perhaps neoplastic transformation. We use a novel FACS based approach to determine if Lethal giant larvae1 (Lgl1) is expressed in OPC. We genetically enforce deletion of Lgl1 in OPC either conventionally with NG2-Cre or conditionally by injecting tamoxifen into triple transgenic mice obtained by breeding Lgl1fl/fl NG2CreERT2 and fluorescence reporter mice. Cre-conditional deleted Lgl1 OPC were analyzed in situ for changes in cell division mode, proliferation rate and differentiation. Whole genome expression analyses were conducted on ex vivo isolated Lgl1 knockout OPC. Lgl1 deletion in embryos leads to tumor formation albeit at low frequency and with long latency. Cre-conditional Lgl1 knockout in adult OPC increases symmetric division and proliferative rate at the expense of asymmetric divisions and differentiation. Whole transcriptome analyses reveal that Lgl1 regulates receptor-mediated endocytosis. Lgl1 loss fails to route NG2 complex to the lysosome for degradation, thereby rapidly increasing NG2 complex levels at the cell membrane and leading to symmetric OPC divisions and immediate premalignant changes such as hyperproliferation.
IMMU-38. GLIOBLASTOMA-DERIVED IL-6 INDUCES IMMUNOSUPPRESSIVE PERIPHERAL MYELOID CELL PD-L1 EXPRESSION AND TUMOR PROGRESSION
Authors: Jonathan Lamano, Jason Lamano, Winward Choy, Dorina Veliceasa, Joseph DiDomenico, Daniel Oyon, Jessica Quaggin-Smith, Shayan Fakurnejad, Leonel Ampie, Derek Li, Kartik Kesavabhotla, Rajwant Kaur, C David James, Andrew Parsa, Orin Bloch
Journal: Neuro-Oncology (2017)

Peripheral myeloid cell PD-L1 expression has been identified as a biomarker of systemic immunosuppression and predictor of vaccine efficacy in GBM. While GBM secreted factors are known to induce an immunosuppressive myeloid phenotype, the specific cytokines regulating PD-L1 remain unidentified. Thus, we sought to characterize tumor-derived PD-L1 inducing factors as therapeutic targets for GBM. To identify PD-L1 inducing factors, patient-derived GBM conditioned media (GCM) was assessed via multiplexed ELISA and used to induce PD-L1 on myeloid cells. GBM patient myeloid PD-L1 expression was quantified via flow cytometry and candidate inducing factors were investigated in plasma. Identified factors were studied in vivo utilizing C57BL/6J mice intracranially implanted with GL261 cells. GCM stimulating high myeloid PD-L1 demonstrated three-fold increased IL-6 expression (p=0.04), identifying IL-6 as a candidate PD-L1 inducing factor. Elevated plasma IL-6 was associated with increased peripheral myeloid PD-L1 in GBM patients (p=0.04) and was found to induce PD-L1 in a STAT3-dependent manner (p=0.005). PD-L1 induction by GCM could be abrogated through treatment with antibodies targeting the IL-6 receptor (tocilizumab, p=0.001) or IL-6 (siltuximab, p=0.02). In addition to immunomodulation, IL-6 also demonstrated proliferative (p=0.004) and invasive (p=0.002) effects on GBM cells that could be diminished through IL-6 inhibition. Tumor-bearing mice demonstrated elevated plasma IL-6 and peripheral myeloid PD-L1 that correlated with tumor burden (R2=0.91, p=0.01). Suppressing IL-6 through tumor cell shRNA knockdown or IL-6 targeted therapy reduced peripheral myeloid PD-L1 (p=0.01), diminished tumor growth (p=0.002), and increased survival (HR=0.21, p=0.004) in murine models. Complementary to murine survival results, TCGA analysis identified elevated IL-6 expression as a predictor of poor survival outcomes in GBM patients (p=0.04). Tumor-derived IL-6 induces peripheral myeloid PD-L1 expression that contributes to systemic immunosuppression in GBM. Furthermore, IL-6 promotes tumor proliferation and invasion. Consequently, targeting IL-6 may serve to improve immunotherapeutic approaches for GBM.
CMET-08. PROGNOSTIC FACTORS AND OUTCOMES OF PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTATIC ALK-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC)
Authors: Ekaterina Kachur, Samantha Reiss, Josiah Land, Larry Buie, Anne Reiner, Katherine Panageas, Gregory Riely, Elena Pentsova
Journal: Neuro-Oncology (2017)

ALK-rearrangement is present in 5% of NSCLC patients. Crizotinib has significantly prolonged progression-free survival (PFS); however, about 70% of patients who progress on crizotinib develop CNS metastases. Prognostic factors for development of CNS metastases in ALK-rearranged NSCLC are unknown. The purpose is to evaluate the impact of patient characteristics and treatment-specific factors on the risk of development of brain metastases (BM) in patients with ALK-rearranged NSCLC. This was an IRB-approved, single-center, retrospective study of patients with stage IIIB or IV ALK-rearranged NSCLC diagnosed between 1/2009 and 2/2017 at Memorial Sloan Kettering Cancer Center. Patient characteristics and treatment were collected. OS and intracranial PFS were calculated using Kaplan-Meier methodology. Cox proportional hazards modeling was used to associate variables with BM, OS, and PFS and to estimate hazard ratios (HR) and 95% confidence intervals (CI). Treatments were modeled in a time-dependent fashion. Ninety-eight patients were identified; 44 (45%) were male, 70 (71%) were Caucasian, and 73 (74%) had Karnofsky performance status (KPS) >70. Twenty (20%) had BM at time of diagnosis and 34 (34%) developed BM at median of 7.5 months (range 0.07 – 62.7) from initial diagnosis. Sixteen (16%) received crizotinib prior to BM diagnosis with trend toward increased risk for development of BM (HR: 2.4, 95%CI:1.0–6.3; p=0.06). Too few patients received ceritinib or alectinib prior to BM diagnosis to model (n=3 and n=0, respectively). Age, sex, and tyrosine kinase inhibitors (TKI) dose reductions were not associated with development of BM. Thirty-eight patients received crizotinib on or after date of BM diagnosis with non-significant increase in risk of death (HR:3.8, 95%CI:0.9–16.1; p=0.07). Only higher KPS score (> 70) was associated with improved OS (HR: 0.15, 95%CI:0.03–0.67; p=0.01). Treatment with crizotinib was associated with trend toward increased risk of development of BM. Only KPS was associated with survival.
MA 17.12 Comparison of EORTC, PERCIST, PeterMac &amp; Deauville PET Response Criteria after Radical ChemoRT in Non-Small-Cell Lung Cancer
Authors: G. Turgeon, A. Iravani, T. Akhurst, J. Callahan, A. Cole, M. Bressel, S. Everitt, S. Siva, D. Ball, M. Mac Manus
Journal: Journal of Thoracic Oncology (2017)